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Abstract
Background: An effective vaccine and new therapeutic methods for hepatitis C virus (HCV) are needed, and a
potent HCV vaccine must induce robust and sustained cellular-mediated immunity (CMI). Research has indicated
that adenoviral and vaccinia vectors may have the ability to elicit strong B and T cell immune responses to target
antigens.
Results: A recombinant replication-defective adenovirus serotype 5 (rAd5) vector, rAd5-CE1E2, and a recombinant
Tian Tan vaccinia vector, rTTV-CE1E2, were constructed to express the HCV CE1E2 gene (1-746 amino acid HCV 1b
subtype). Mice were prime-immunised with rAd5-CE1E2 delivered via intramuscular injection (i.m.), intranasal
injection (i.n.), or intradermal injection (i.d.) and boosted using a different combination of injection routes. CMI was
evaluated via IFN-g ELISPOT and ICS 2 weeks after immunisation, or 16 weeks after boost for long-term responses.
The humoral response was analysed by ELISA. With the exception of priming by i.n. injection, a robust CMI
response against multiple HCV antigens (core, E1, E2) was elicited and remained at a high level for a long period
(16 weeks post-vaccination) in mice. However, i.n. priming elicited the highest anti-core antibody levels. Priming
with i.d. rAd5-CE1E2 and boosting with i.d. rTTV-CE1E2 carried out simultaneously enhanced CMI and the humoral
immune response, compared to the homologous rAd5-CE1E2 immune groups. All regimens demonstrated
equivalent cross-protective potency in a heterologous surrogate challenge assay based on a recombinant HCV
(JFH1, 2a) vaccinia virus.
Conclusions: Our data suggest that a rAd5-CE1E2-based HCV vaccine would be capable of eliciting an effective
immune response and cross-protection. These findings have important implications for the development of T cell-
based HCV vaccine candidates.
Background
Hepatitis C virus (HCV) is one of the major agents of
acute and chronic hepatitis worldwide [1,2]. Around
80% of HCV infections progress to chronic hepatitis. In
turn, chronic hepatitis C infection frequently progresses
to cirrhosis, and a significant proportion of patients with
liver cirrhosis will develop hepatocellular carcinoma
(HCC) [3]. Treatment of chronic hepatitis C with inter-
feron alpha and ribavirin is effective in less than 50% of
cases [4,5]. Considerable effort has been directed toward
development of a safe and effective HCV vaccine, but
without any significant clinical success [6]. Thus the
development of such a vaccine is vital [7].
A key feature of most vaccines is induction of neutra-
lising antibodies. The genetic variability of HCV is enor-
mous; the site of greatest variability is within the E2
envelope glycoprotein (hypervariable region 1), a major
target of neutralising antibodies [8]. Studies in both
humans and chimpanzees have yet to demonstrate a
clear humoral immune correlation with viral clearance
[9-11]. In contrast, some investigations have suggested
that strong HCV-specific cytotoxic T cell (CTL)
responses are likely to be important in viral clearance
and possibly protection [10-19]. Viral persistence is
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T cell response [15-17]. Studies have indicated that con-
trol of an acute HCV infection is associated with a vig-
orous, broadly-directed, and sustained activation of
HCV-specific T cells [9-11,18]. Therefore, engineering
an efficient adaptive immune response, especially a T
cell response, should be the goal of any HCV vaccine
strategy [1,6,7].
At present, little is known about the association
between the structural protein (C/E1/E2)-specific T cell
responses induced by different immunisation strategies
and the accompanying antiviral protection [1,15,19]. We
hypothesise that vaccines expressing HCV structural
proteins and containing the most conserved core and
immunodominant E1/E2 could elicit highly cross-reac-
tive and protective T cell immunity to various HCV
genotypes. This may be crucial for elucidating the corre-
lations between vaccine immunity and protection as well
as for identifying the optimal design of candidate vac-
cines [1,6,7,11]. In this study, we developed a T cell-
directed vaccine using replication-defective adenoviruses
expressing HCV structural antigens.
Adenoviral vectors are attractive carriers for genetic
vaccines because of their strong immunogenicity and
their ability to transduce antigen-presenting cells (APCs)
and elicit strong B and T cell immune responses to tar-
get antigens [20]. In mice and nonhuman primates,
recombinant adenoviral 5 (rAd5) vector-based immuno-
gens induce strong T cell responses toward a variety of
target antigens [20-24]. Currently, several rAd5-based
vaccines against a variety of infectious agents are in the
preclinical and clinical stages of development [20-25].
However, pre-existing anti-Ad immunity can signifi-
cantly dampen the response to the vaccine [20,21]. Pre-
vious reports have suggested that optimisation of
delivery routes and regimens might overcome this lim-
itation [20,21]. However, to the best of our knowledge,
few studies have presented data on the immunity
induced by rAd5-based HCV vaccines delivered via dif-
ferent routes and regimens.
No inexpensive animal model of HCV for vaccine eva-
luation currently exists [26]. One of the more easily
available and more commonly used murine models is
infection with a recombinant vaccinia virus encoding
the protein of interest [23,24,27]. This surrogate model
of HCV infection has been used to evaluate a variety of
vaccine platforms, including a subunit protein, plasmid
DNA, and human adenovirus vaccines [23,24,27].
In this study, we constructed an rAd5 vector expres-
sing the HCV structural genes CE1E2 (rAd5-CE1E2)
and a recombinant Tian Tan Vaccinia viral vector
( r T T V )[ 2 8 ]e x p r e s s i n gt h es a m eH C Vt a r g e tp r o t e i n s
(rTTV-CE1E2). We evaluated their immunogenicity via
different delivery routes and regimens to optimise the
immune response. Moreover, we characterised cross-
protection in different groups of mice using a heterolo-
gous surrogate challenge assay based on a recombinant
HCV (JFH1, 2a) vaccinia virus.
Results
Construction and expression of recombinant viral vector-
based HCV vaccines
We constructed an rAd5-based vaccine (rAd5-CE1E2)
expressing the HCV structural gene CE1E2 (Figure 1),
as well as a recombinant vaccinia virus expressing the
HCV structural gene CE1E2 (rTTV-CE1E2) (Figure 1).
Expression of the target proteins was confirmed by
Western blotting using a mouse mAb to the HCV core,
E1, and E2 proteins (Figure 2A). All of the proteins
were expressed as previously described in cell lysates
infected with rAd5-CE1E2 or rTTV-CE1E2.
Single vaccination with rAd5-CE1E2 induced significant
CMI in mice
To To compare the CMI response elicited by the various
injection routes, we performed ELISPOT after a single
vaccination. Splenocytes were harvested 2 weeks after
immunisation and stimulated with an HCV peptide pool
representing the core, E1, or E2 proteins. IFN-g-positive
spot-forming cells (SFCs) against the E1 or E2-2 peptide
pools were detected in all immunised groups, whereas
spots against the core peptide pool were detected in all
groups. The cellular immune responses against E1 were
much stronger than those against the core or E2 proteins.
During E1 peptide pool screening we identified a single
peptide, E1-21 (SQLFTFSPRRYETI), which had a high
affinity. The group immunised via i.n. had significantly
fewer SFCs than did the i.m. and i.d. groups; there were
no significant differences between the i.m. and i.d. groups
(Figure 3A).
Prime-boost vaccination induces robust and sustained
CMI in mice
To further compare the immunogenicity of rAd5-based
HCV vaccines among different delivery routes and regi-
mens, we used different vaccination combinations and
monitored their effects via ELISPOT at 2 or 16 weeks
Figure 1 Schematic representation of recombinant viral vectors
encoding the HCV structural gene. ITR, inverted terminal repeat;
P7.5K, P7.5 later promoter; P11K, P11 later promoter; TKR, right
thymidine kinase; TKL, left thymidine kinase.
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immune group (rAd5+rTTV) had more SFCs than the
homologous immune groups (rAd5 only), and the i.n.
priming group (rAd5 i.n.+i.m.) had fewer SFCs than the
other groups (rAd5 i.m.+i.m., rAd5 i.m.+i.n.); these dif-
ferences were statistically significant (Figure 3B). The
CMI remained at a high level for a long period (over 16
weeks) in each of the prime-boost groups (Figure 3C),
and the response level in each group was parallel to that
detected (Figure 3B).
To examine the CTL response more quantitatively, we
performed ICS on the immunised mice. Splenocytes iso-
lated at week 22 (16 weeks post-boost) were stimulated
in vitro with the peptide E1-21. In Figure 4A, the num-
ber in the right-hand corner of each graph indicates the
percentage of CD8+ cells that stained positive for IFN-g.
As shown in Figure 4B, the percentage of CD8+T cells
that stained positive for IFN-g in the heterologous
immune group was higher than that in the other groups.
Also, and similar to the ELISPOT results, among the
homologous immune groups, the percentage of IFN-g
+CD8+T cells in the group primed via i.n. (Ad i.n.+i.m.)
was significantly lower than in the other groups (rAd5 i.
m.+i.m., rAd5 i.m.+i.n.).
Humoral immune response in mice detected by ELISA
To assess the humoral immune response in mice
induced by rAd5-CE1E2/rTTVCE1E2 vaccination, we
monitored IgG antibody levels against the core, E1, and
E2 proteins via ELISA (Table 1). The patterns of anti-E1
and anti-E2 antibody levels were identical to those of
the T cell responses. Interestingly, and contrary to the T
cell responses, the anti-core antibody titre of the i.n.
priming group (Ad i.n.+i.m.) was markedly higher than
the others, except for the heterologous prime-boost
(rAd5 +rTTV) group. The humoral immune responses
against HCV (IgG antibody anti-core/E1/E2) in the het-
erologous prime-boost (rAd5 +rTTV) group were much
Figure 2 Western blot analysis of HCV antigen expression of
rAd5-CE1E2 and rTTV-CE1E2. The expression of HCV antigen in
HeLa cells infected with recombinant virus was detected by
Western blot. Cell lysates were subjected to SDS-PAGE followed by
immunoblotting with antibodies specific for the individual antigens,
as described in the methods. The expression bands of E1, E2, and
Core proteins and their molecular weights are indicated.
Figure 3 Cellular immune responses in rAd5-CE1E2 immunised mice. An ELISPOT assay of splenocytes after stimulation with an HCV
peptide pool representing the core, E1, or E2 proteins. Splenocytes were isolated at weeks 2 (A, post-prime), 5 (B, post-boost), and 20 (C, long-
term). The data are expressed as spot-forming cell (SFC) responses to different peptide pools, and are presented as means with SEM of six mice
per group. Significant p values between the vaccinated groups are shown. Control group mice injected with PBS generated SFC responses of <
20 per 106 mononuclear cells. Significant p values between vaccinated groups are shown. * indicates p < 0.05, ** indicates p < 0.01.
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(rAd5 i.m.+i.m., rAd5 i.m.+i.n.). Anti-adenoviral anti-
body levels were also evaluated by ELISA. IgG titres
were > 8000 in the single-immunised groups and >
20000 in the prime-boost vaccination groups (Table 1).
These data indicate that injections were successfully
administered to each mouse.
rAd5-HCV vaccination induced cross-protection in a
surrogate challenge model
To assess the effects of the immunity induced by rAd5-
CE1E2 (1b), 1 × 107 pfu heterologous rTTV-JFH1(2a)
was inoculated into immunised mice 8 weeks after the
final injection. Mice were sacrificed 5 days after chal-
lenge. Then vaccinia titres in the ovaries were deter-
m i n e d .A ss h o w ni nF i g u r e5 ,t h ei m m u n i s e dg r o u p s
were protected from heterologous challenge and showed
significantly different responses than the control group.
However, there were no significant differences among
the immunised groups.
Discussion
Development of a B-cell-based vaccine is difficult due to
the high genetic variability of HCV [6-8]. A potent vac-
cine should induce a strong and long-term protective T
cell response [6,7]. We constructed an rAd5-based and
rTTV-based HCV vaccine expressing the HCV struc-
tural gene CE1E2 from HCV genotype 1b. We identified
the antigenic composition of the vaccine vectors and
evaluated their immunogenicity via different delivery
routes and regimens. Our results indicate that those
vaccines were able to elicit a CMI response against the
HCV core, E1, and E2 antigens in mice. The response
Table 1 Humoral responses (anti-HCV IgG) in immunised groups detected by ELISA.
IgG Antibody titer
Ad (i.m.) Ad (i.d.) Ad (i.n.) Ad (i.m.+i.m.) Ad (i.m.+i.n.) Ad (i.n.+i.m.) Ad (id)/TTV(id)
Anti-core 50 50 50 50 50 3200 400
Anti-E1 100 100 25 200 200 100 1600
Anti-E2 100 100 25 800 400 100 1600
Note: Antisera were collected 14 days post-immunization, and total IgG titres specific for the HCV antigen were determined by ELISA as described in the
methods. Numbers represent titres of pooled sera from each group. Experiments were repeated at least three times and same results were obtained. The
antibody titre was defined as the reciprocal of the serum dilution at which the absorbance (OD value) was twice that of sera in the non-immunized group.
Figure 5 Vaccinia titres in immunised mice challenged with
rTTV-CE1E2. Mice were sacrificed 5 days post-challenge. Vaccinia
titres in ovaries were determined. Mice (five or six per group)
received a single immunisation (Figure 5A). Mice (six per group)
received two immunisations and were challenged after the second
(booster) immunisation (Figure 5B). The data are presented as the
mean with SEM of each group. Significant p values between the
vaccinated groups are shown. * indicates p < 0.05, ** indicates p <
0.01.
Figure 4 CD8+ T-cell response obtained by ICS in rAd5-CE1E2
and rTTV-CE1E2 immunised mice. Splenocytes isolated at week
20 were stimulated in vitro with peptide E1-21 (SQLFTFSPRRYETI)
alone. Representative fluorescence-activated cell sorter flowgrams
are shown in Figure 4A (percentages of IFN-g+CD8+cells are shown
in the right upper quadrants), and a summary of the percentages of
IFN-g-producing CD8+cells are presented in Figure 4B as the mean
with SEM of four mice per group. Significant p values between the
vaccinated groups are shown. * indicates p < 0.05, ** indicates p <
0.01.
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vaccination). Induction of cross-protection by rAd5-
based HCV CE1E2-induced responses were confirmed
in vivo using a heterologous surrogate challenge assay
based on a recombinant HCV (JFH1,2a) vaccinia virus.
Since it was discovered that T cells are important for
clearance of HCV, a great deal of focus has been on
developing vaccines that will induce T cell responses to
HCV proteins [6,7]. A number of approaches, including
the use of virus-like particles (VLPs) and defective or
attenuated viral vectors with or without a prime-boost
strategy, have been used to generate T cell responses
against HCV antigens [6,7]. The use of HCV VLPs pro-
duced in insect cells has proven successful for inducing
effective HCV-specific immune responses [29]. Interest-
ingly, in these VLP studies, responses to the structural
proteins were mainly specific to T cells with little or no
neutralising antibody detected, and all responses
resulted in modification of HCV infection and early
control of replication following virus challenge [29]. In
addition, a metaanalysis of HCV vaccine efficacy in
chimpanzees indicated the importance of structural pro-
teins that may activate T cell responses and thus med-
iate viral clearance [30]. We chose the structural
proteins (1-746 amino acids [aa]) of the HCV isolates
dominant in China (1b) as immunogens. This choice
was also based on the fact that a similar structural gene
(1-746 aa) can be assembled as a VLP when expressed
in insect cells [29]. Western blot analysis indicated that
the core, E1, and E2 proteins were expressed efficiently
in cells infected with rAd5-CE1E2 vaccine.
The viral vectors used for HCV T cell vaccines,
including adenovirus and vaccinia virus vectors, are
common to a number of strategies used for other infec-
tious agents (such as HIV and TB) [6,7,20-25,31,32]. A
greater number of rAd5-based HCV vaccine candidates
have successfully induced HCV-specific immune
responses [23,24,31]. Interestingly, an adenovirus vector-
based minigene vaccine encompassing the four domains
of the HCV NS3, NS4, NS4A, and NS5B proteins that
contain multiple class I/II restricted epitopes also
induced strong and broad HCV specific T cell responses
in HLA-A2 transgenic mice and may prove promising
as a tool for inducing cross-reactive responses [31]. An
extremely encouraging study reported that an rAd-based
T cell vaccine expressing the NS3-NS4-NS5A-NS5B
antigens elicited non-sterile, yet protective, immunity in
four of five challenged chimpanzees [25]. Protection in
this study was correlated with T cell responses, in parti-
cular with CD8+T cell-mediated immunity. Based on
these reports, we selected rAd as a vector to carry the
immunogen. In addition, an attenuated recombinant
vaccinia virus (Tian Tan strain) was selected as a vector
[33]. The data indicated that an rAd5-based HCV
vaccine can elicit multi-antigen, robust, and long-lasting
IFN-g-producing CD8+T cell-mediated immunity in
mice, with cross-protection. In addition, a heterologous
rAd5/rTTV regimen elicited the strongest CMI and E1/
E2-specific humoral immune response, compared to a
homologous rAd5 regimen. These data are in accor-
dance with previous studies of the T cell responses eli-
cited by rAd-based HIV or HCV vaccines [20-22].
Despite the current controversies concerning the use of
rAd-based vaccines for HIV-1, we demonstrated here
that an rAd5-CE1E2-based T cell vaccine for HCV has
significant cross-protective efficacy in our surrogate
challenge model. The data in this proof-of-concept
study have important implications for the application of
novel T cell-based HCV vaccines.
The majority of rAd5-HCV vaccines have been tested
in animal model via the i.m. or i.p. route. There are lim-
ited data in the literature comparing the immunogeni-
city and protection elicited by various rAd5-based HCV
vaccine delivery routes and regimens. Thus, we assessed
the humoral and cellular immune responses and cross-
protection elicited in mice immunised via different
delivery routes (i.m., i.n., i.d.) and regimens. The
immune effects of each delivery route differed. Com-
pared to the i.n. route, one injection of rAd-CE1E2
induced a stronger cellular immune response to the
HCV structural gene when administered via i.m. or i.d.
Similarly, priming via i.n. induced a lower IFN-g T cell
response than did i.m priming. These results demon-
strate that the priming route may be an important
determinant of immune effects. Of the two-injection
groups, an rTTV-CE1E2 boost following rAd-CE1E2
priming induced the strongest T cell responses to the
HCV core, E1, and E2 proteins. Similar to the cellular
responses, the heterologous regimen induced the stron-
gest antibody response to E1 and E2, while the homolo-
gous i.n.-primed group resulted in the lowest antibody
levels. Curiously, for the anti-core antibody, the titre in
the i.n.-primed homologous group was much higher
than in the other groups. No significant neutralising
antibody response was observed among the groups
based on an HCVpp assay (data not shown). Both the
antibody and CMI responses could be boosted further
in our model system, because even the pre-existing anti-
Ad5 IgG antibody levels in the immunised groups were
high (Table 1).
T h em a j o r i t yo fv a c c i n es t u d i e sh a v eu s e dah o m o l o -
gous virus challenge, i.e., the same genotype as the virus
contained in the vaccine. In this study, we used a het-
erologous challenge model developed in our lab, which
used a different subtype (2a) virus expressing an HCV-
polyprotein with an approximately 18% genetic differ-
ence from the vaccine-based sequence (1b). We demon-
strated in this model that vaccination of mice with an
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titre of rHCV-JFH1, and was able to fully protect immu-
nised mice, although the i.n.-immunised and i.n.-primed
regimens induced the weakest T cell responses. These
results indicate that other mechanisms, such as antibody
(core), are involved in protective immunity to HCV, not
only the level of IFN-g-producing T cells detected by
ELISPOT or ICS. It remains possible, however, that
other aspects of the CMI response may contribute to
cross-protection of HCV vaccines [34]. In addition, the
potential role of antibody-dependent cell-mediated virus
inhibition (ADCVI) [35] should also be explored in a
future study. Development of an immunocompetent
small animal model would advance the field enormously
[36], although care should always be taken in extrapolat-
ing data to humans, as many immune response studies
in mice have not translated well to humans and other
primates.
Conclusions
We developed an HCV candidate vaccine based on an
rAd5-vector and structural protein (CE1E2) immunogen.
This vaccine elicits a potent and long-lasting boost dur-
ing in vivo cross-reactive T cell-mediated immune
responses with a single or double vaccination by different
routes (i.n., i.m., i.d.) or combinations of routes (i.m.+i.
m., i.m.+i.n., i.n.+i.m.). However, the humoral immune
response (especially the neutralising antibody titre) was
not strong. Our data support the idea that an rAd5-
CE1E2-based HCV vaccine would show promise against
HCV infection, and would be capable of inducing cross-
protection. However, the protective potency was corre-
lated not only with the IFN-g SFC level, as detected by
ELISPOT or ICS, it was correlated with other as-yet-uni-
dentified factors that need to investigated further. There
is still a great deal of missing information regarding the
types of immune responses that correlate with protection
or clearance of HCV after vaccination. New vaccine stu-
dies should also employ higher-level immunological ana-
lyses that examine the multifunctional activities of T cells
and T cell phenotypes.
Methods
Generation of recombinant viruses
The HCV CE1E2 gene (1-746 aa HCV 1b subtype,
Hebei isolate [37], NCBI accession no. L02836) was
used to construct the rAd5-CE1E2 vector (Figure 1).
T h ea d e n o v i r u st y p e5c o n s t r u c ti sap r o t o t y p i cf i r s t -
generation vector containing an E1 deletion replaced
with the HCV CE1E2 expression cassette. As the E1
deletion renders it replication-defective, the vector was
propagated in HEK293 cells, which provided E1 in
trans. The recombinant Ad5-virus was generated as
reported previously [38]. The rAd5-CE1E2 vector was
purified and amplified in HEK293 cells.
The original TTV strain and dual-promoter insertion
vector pJSA1175 were produced in our laboratory
[28,33]. The HCV CE1E2 gene was inserted into the
SmaI site of the pJSA1175 vector. The rTTV vector was
produced by transfection of pJSA1175-CE1E2 into CEF
cells that were infected with TTV, and was designated
rTTV-CE1E2 (Figure 1).
To obtain heterologous surrogate challenge viruses,
the full-length ORF (1-3011 aa) gene from the HCV
JFH1 (2a) strain was inserted into the SmaI site of the
pJSA1175 vector. Insertion was followed by transfection
of pJSA1175-JFH1 into CEF cells that had been infected
by TTV. The resulting vector was designated rTTV-
JFH1 (2a). The virus stock was purified and titrated as
described previously [28,33].
Characterisation of the immunogen
Expression of the target protein was identified by Wes-
tern blot using a mouse mAb to the HCV core, E1, and
E2 proteins. HeLa cells infected with recombinant virus
were collected after 48 h, and processed by cell lysis (50
mM Tris pH 7.5, 70 mM b-mercaptoethanol). Lysates
were then separated on a 10% or 15% polyacrylamide
gel and transferred by electroblotting to a polyvinylidene
fluoride (PVDF) membrane. The membrane was blocked
for 1 h with 5% skim milk at 37°C and then incubated
with monoclonal antibody (mAb) to the HCV core
(ABR) or E1 (ABR) or E2 (AP33, from Dr. H. Patel) pro-
teins overnight at 4°C. After being washed three times
with phosphate-buffered saline (PBS) containing 0.5%
Tween-20 (PBST), the membrane was protected from
light and incubated with goat anti-mouse antibody
(IRDye 800) for 1 h at 37°C. After washing three times
in PBST, bands were detected using an infrared imaging
system.
Immunisation and challenge
Groups of female BalB/c mice were immunised at 6-8
weeks of age. They were divided into three groups and
immunised once with rAd5-CE1E2 administered by
intramuscular injection (i.m.), intranasal injection (i.n.),
or intradermal injection (i.d.). The three homologous
immune groups were then immunised with rAd5-CE1E2
as prime immunisation via i.m., i.m., or i.n., and boosted
via i.m., i.n., or i.m., respectively, at 6-week intervals.
Mice in one heterologous immunisation group were
primed with rAd5-CE1E2 and boosted with rTTV-
CE1E2 at 6-week intervals. In addition, mice immunised
with PBS were used as controls. The viral doses were 5
× 109 vp/mouse for rAd5-CE1E2 or 1 × 107 pfu/mouse
for rTTV-CE1E2.
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challenged with 1 × 107 pfu of rTTV-JFH1 (2a) by
intraperitoneal injection (i.p.). They were sacrificed 5
days after challenge (peak vaccinia titre in ovaries), and
their were ovaries harvested. After a freeze-thaw and
homogenisation procedure, the vaccinia titre was deter-
mined by plaque assay using chicken embryo cells
[28,31].
Immune response analysis of vaccinated mice
A peptide library of HCV structural proteins (C/E1/
E2), based on the Hebei isolate sequence of HCV gen-
otype 1b, was synthesised as lengths of 13-17 aa with
an overlap of 10 aa between fragments (ZhongKeYa-
Guan Co., Beijing, China). Peptides were dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 50
mg/ml. The core and E1 peptide pools contained 42
and 39 peptides, respectively. The E2 peptide pool
contained 79 peptides separated into two pools: E2-1
(40 peptides) and E2-2 (39 peptides). The peptide
pools were aliquoted, stored at -20°C, and used at a
final concentration of 4 μg/ml.
Enzyme-linked immunospot (ELISPOT) assays
Splenocytes were harvested at 2 weeks post-immunisa-
tion and stimulated with the HCV peptide pools. Briefly,
multiscreen 96-well plates were coated overnight with
100 μl per well of 5 μg/ml anti-mouse gamma interferon
antibody (IFN-g) (BD Pharmingen) in PBS. Then the
plates were washed three times with RPMI 1640 con-
taining 10% FBS, blocked for 2 h with RPMI 1640 con-
taining 10% FBS, and incubated with peptide pools and
mononuclear spleen cells (MNCs) in triplicate in 100 μl
reaction mixture volumes. The peptide pools used in
this study spanned the HCV core, E1, and E2 proteins
and comprised 13-17 aa peptides. Each peptide in a
pool was present at a concentration of 4 μg/ml. Follow-
ing incubation for 20-24 h at 37°C, cell suspensions
were aspirated. The wells were washed twice with deio-
nised (DI) water. Wells were allowed to soak for 3-5
min at each wash step. Then the wells were washed
three times with 200 μl PBST before the addition of 100
μl detection antibody solution (BD Pharmingen). The lid
was replaced and the plates were incubated for 2 h at
room temperature. Then the wells were washed three
times with 200 μl PBS, being allowed to soak for 1-2
min at each wash step. A prepared streptavidin-HRP
solution was added at 100 μl per well and the plates
were incubated for 1 h at room temperature, followed
by four washes, and the addition of 100 μlp r e p a r e d
AEC substrate solution to each well. Spot development
was monitored for 5-60 min. The reaction was stopped
by washing with DI water. Plates were air-dried at room
temperature and stored in a sealed plastic bag in the
dark until analysis in an ELISPOT plate reader.
Intracellular cytokine staining(ICS)
Splenocytes (2 × 106/sample) were cultured for 5 h at
37°C in 96-well round-bottom microtitre plates in 1640
supplemented with 10% FBS, and peptide E1-21
(SQLFTFSPRRYETI) and Brefeldin A (GolgiPlug; BD
PharMingen) were added simultaneously. The E1-21
peptide was used at a concentration of 4 μg/ml. Control
cells were incubated with an unrelated peptide or with-
out any peptide. After washing, cells were incubated for
30 min at 4°C with 25 μl of a 1/100 dilution of a PE-
labelled Ab to mouse CD8 and FITC-labelled Ab to
mouse CD4 (BD PharMingen). The cells were washed
again and permeabilised in 1 × Cytofix/Cytoperm (BD
PharMingen) for 20 min at 4°C, washed three times
with Perm/Wash (BD PharMingen), and then incubated
in the same buffer for 30 min at 4°C with 50 μlo fa1 /
100 dilution of an APC-labelled Ab to mouse IFN-g (BD
PharMingen). After washing, the cells were examined by
three-color flow cytometry.
Enzyme-linked immunosorbent assay (ELISA)
Sera from animals were pooled, and diluted sera were
applied to a 96-well plate previously coated with solu-
ble E1 or E2 protein [39] for detection of anti-E1 or
anti-E2 antibody, or coated with antigen containing
the core and NS3 HCV fusion (Wantai Co., China) for
anti-core antibody detection, or with recombinant ade-
novirus (mock) for anti-Ad antibody detection. Then
the plates were blocked with skim milk and incubated
for 1 h at 37°C. After washing with PBST, peroxidase-
conjugated goat anti-mouse IgG was added and the
plates were incubated for a further hour followed by a
wash. A colour reaction was induced by adding 3,3,5,5-
tetramethylbenzidine (TMB) peroxidase substrate solu-
tion. The reaction was stopped by adding 1 M H2SO4,
and the absorbance was read at 450 nm. The antibody
titre was defined as the reciprocal of the serum dilu-
tion at which the absorbance was twice that of sera of
unimmunised mice.
Data analysis
Significant differences between the experimental and
control groups were evaluated using the one-way
ANOVA analysis function in the SPSS software package
(release 12.1; SPSS Inc., Chicago, IL). Differences were
considered significant at p < 0.05.
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